Immunization with DNA topoisomerase I induces autoimmune responses but not scleroderma-like pathologies in mice

Journal of Rheumatology

Volumn 34, Issue 11, 2007, Pages 2243-2252

  Hu, Paul Q ^a   Hurwitz, Arthur A ^a   Oppenheim, Joost J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody; Autoimmunity; DNA topoisomerase I; Skin; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; DNA TOPOISOMERASE; DNA TOPOISOMERASE 1 ANTIBODY; GAMMA INTERFERON; HUMAN RECOMBINANT TOPO 1 ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; AUTOPSY; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TRACT; HEART; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOPATHOGENESIS; JOINT; KIDNEY; LUNG; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SCLERODERMA; SKIN; SKINFOLD; SPLEEN LYMPHOCYTE; WEIGHT REDUCTION;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; AUTOANTIBODIES; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; DNA TOPOISOMERASES, TYPE I, EUKARYOTIC; FEMALE; HUMANS; IMMUNIZATION; IMMUNIZATION, SECONDARY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, MUTANT STRAINS; RECOMBINANT PROTEINS; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTES;

EID: 35948938967     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Rantapaa-Dahlqvist S. Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis. Scand J Rheumatol 2005;34:83-96.
2. Bridges SL. Update on autoantibodies in rheumatoid arthritis. Curr Rheumatol Rep 2004;6:343-50.
3. van Boekel MA, Vossenaar ER, van den Hoogen FH, et al. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002;4:87-93.
4. Gordon TP, Bolstad AI, Rischmueller M, Jonsson R, Waterman SA. Autoantibodies in primary Sjogren's syndrome: new insights into mechanisms of autoantibody diversification and disease pathogenesis. Autoimmunity 2001;34:123-32.
5. Sawalha AH, Harley JB. Antinuclear autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol 2004;16:534-40.
6. Smolen JS, Hassfeld W, Graninger W, Steiner G. Antibodies to antinuclear subsets in systemic lupus erythematosus and rheumatoid arthritis. Clin Exp Rheumatol 1990;8 Suppl 5:41-4.
7. Reimer G, Steen VD, Penning CA, Medsger TA Jr, Tan EM. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1988;31:525-32.
8. Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980;23:617-25.
9. Ascherman DP. The role of Jo-1 in the immunopathogenesis of polymyositis: current hypotheses. Curr Rheumatol Rep 2003;5:425-30.
10. Jimenez SA, Sigal SH. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheumatol 1991;18:1496-503.
11. Hochberg MC, Perlmutter DL, Medsger TA, et al. Lack of association between augmentation mammoplasty and systemic sclerosis (scleroderma). Arthritis Rheum 1996;39:1125-31.
12. Weiner ES, Earnshaw WC, Senecal JL, Bordwell B, Johnson P, Rothfield NF. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum 1988;31:378-85.
13. Morel PA, Chang HJ, Wilson JW, et al. Severe systemic sclerosis with anti-topoisomerase I antibodies is associated with an HLA-DRw11 allele. Hum Immunol 1994;40:101-10.
14. Hu PQ, Fertig N, Medsger TA Jr, Wright TM. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003;48:1363-73.
15. Sato S, Hamaguchi Y, Hasegawa M, Takehara K. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology Oxford 2001;40:1135-40.
16. Kuwana M, Feghali CA, Medsger TA Jr, Wright TM. Autoreactive T cells to topoisomerase I in monozygotic twins discordant for systemic sclerosis. Arthritis Rheum 2001;44:1654-9.
17. Muryoi T, Kasturi KN, Kafina MJ, et al. Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes. J Exp Med 1992;175:1103-9.
18. Kasturi KN, Shibata S, Muryoi T, Bona CA, Tight-skin mouse: an experimental model for scleroderma. Int Rev Immunol 1994;11:253-71.
19. Hatakeyama A, Kasturi KN, Wolf I, Phelps RG, Bona CA, Correlation between the concentration of serum anti-topoisomerase I autoantibodies and histological and biochemical alterations in the skin of tight skin mice. Cell Immunol 1996;167:135-40.
20. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998;279:1504-13.
21. D'Arpa P, Machlin PS, Ratrie H 3rd, Rothfield NF, Cleveland DW, Earnshaw WC. cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment. Proc Natl Acad Sci USA 1988;85:2543-7.
22. Engelhorn ME, Guevara-Patino JA, Noffz G, et al, Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med 2006;12:198-206.
23. Hurwitz AA, Sullivan TJ, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proc Natl Acad Sci USA 2002;99:3013-7.
24. Hu PQ, Fertig N, Medsger TA Jr, Wright TM. Molecular recognition patterns of serum anti-DNA topoisomerase I antibody in systemic sclerosis. J Immunol 2004;173:2834-41.
25. Humphreys-Beher MG, Brinkley L, Purushotham KR, et al. Characterization of antinuclear autoantibodies present in the serum from nonobese diabetic (NOD) mice. Clin Immunol Immunopathol 1993;68:350-6.
26. Maul GG, Jimenez SA, Riggs E, Ziemnicka-Kotula D. Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis. Proc Natl Acad Sci USA 1989;86:8492-6.
27. Verheijen R, Van den Hoogen F, Beijer R, et al. A recombinant topoisomerase I used for autoantibody detection in sera from patients with systemic sclerosis. Clin Exp Immunol 1990;80:38-43.
28. D'Arpa P, White-Cooper H, Cleveland DW, Rothfield NF, Earnshaw WC. Use of molecular cloning methods to map the distribution of epitopes on topoisomerase I (Scl-70) recognized by sera of scleroderma patients. Arthritis Rheum 1990;33:1501-11.
29. Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000;43:1074-84.
30. Piccinini G, Cardellini E, Reimer G, Arnett FC, Durban E. An antigenic region of topoisomerase I in DNA polymerase chain reaction-generated fragments recognized by autoantibodies of scleroderma patients. Mol Immunol 1991;28:333-9.
31. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-52.
32. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006;18:206-13.
33. Pablos JL, Everett ET, Norris JS. The tight skin mouse: an animal model of systemic sclerosis. Clin Exp Rheumatol 2004;22:S81-5.
34. Lakos G, Takagawa S, Varga J. Animal models of scleroderma. Methods Mol Med 2004;102:377-93.
35. Poole BD, Scofield RH, Harley JB, James JA. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 2006;39:63-70.
36. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
37. Fukuyama H, Nimmerjahn F, Ravetch JV. The inhibitory Fc-gamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol 2005;6:99-106.
38. Bagavant H, Fu SM. New insights from murine lupus: disassociation of autoimmunity and end organ damage and the role of T cells. Curr Opin Rheumatol 2005;17:523-8.
39. Ansell BM, Nasseh GA, Bywaters EG. Scleroderma in childhood. Ann Rheum Dis 1976;35:189-97.
40. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV, TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006;203:553-61.
41. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005;202:321-31.
42. Asano N, Fujimoto M, Yazawa N, et al, B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol 2004;165:641-50.
43. Ramirez-Sandoval R, Sanchez-Rodriguez SH, Herrera-van Oostdam D, Avalos-Diaz E, Herrera-Esparza R. Antinuclear antibodies recognize cellular autoantigens driven by apoptosis. Joint Bone Spine 2003;70:187-94.
44. Frisoni L, McPhie L, Colonna L, et al. Nuclear autoantigen translocation and autoantibody opsonization lead to increased dendritic cell phagocytosis and presentation of nuclear antigens: a novel pathogenic pathway for autoimmunity? J Immunol 2005;175:2692-701.
45. Chizzolini C, Raschi E, Rezzonico R, et al, Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002;46:1602-13.
46. Henault J, Robitaille G, Senecal JL, et al. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 2006;54:963-73.